{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:15:08Z","timestamp":1791843308168,"version":"4.3.4"},"reference-count":8,"publisher":"Centers for Disease Control MMWR Office","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7108a1","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T15:59:11Z","timestamp":1645718351000},"page":"285-289","source":"Crossref","is-referenced-by-count":89,"title":["Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis \u2014 United States, 2022"],"prefix":"10.15585","volume":"71","author":[{"given":"Wendy","family":"Carr","sequence":"first","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Kurbatova","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Starks","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neela","family":"Goswami","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeanna","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Winston","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"key-10.15585\/mmwr.mm7108a1-202202241025-R1","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis.","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm7108a1-202202241025-R2","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis.","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7108a1-202202241025-R3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials.","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.15585\/mmwr.mm7108a1-202202241025-R4","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1371\/journal.pmed.0040344","article-title":"Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.","volume":"4","author":"Rosenthal","year":"2007","journal-title":"PLoS Med"},{"key":"key-10.15585\/mmwr.mm7108a1-202202241025-R5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.","volume":"191","author":"Dorman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.15585\/mmwr.mm7108a1-202202241025-R6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1164\/rccm.200507-1072OC","article-title":"Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis.","volume":"172","author":"Rosenthal","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.15585\/mmwr.mm7108a1-202202241025-R7","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline.","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.15585\/mmwr.mm7108a1-202202241025-R8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T15:59:14Z","timestamp":1645718354000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7108a1.htm?s_cid=mm7108a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":8,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,2,25]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7108a1","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,25]]},"published":{"date-parts":[[2022,2,25]]}}}